Levodropropizine

Levodropropizine

• CAS Number: 99291-25-5
• UNSPSC Description: Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent[1].
• Target Antigen: Histamine Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Endocrinology; Inflammation/Immunology; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/Levodropropizine.html
• Purity: 99.71
• Solubility: DMSO : ≥ 50 mg/mL|H2O : 10 mg/mL (ultrasonic)
• Smiles: OC[C@@H](O)CN1CCN(C2=CC=CC=C2)CC1
• Molecular Weight: 236.31
• References & Citations: [1]Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10(1):19.|[2]Luo YL, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62(12):1053-61.|[3]Erdogan MA, et al. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy. Epilepsy Res. 2019 Feb;150:32-37. |[4]Yamawaki I, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993 Oct 12;243(1):1-6.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched